{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:12:33Z","timestamp":1783977153853,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rituximab is employed in the treatment of B-cell non-Hodgkin lymphomas (NHL) and autoimmune disorders of hematological interest (ADHI), such as autoimmune hemolytic anemia (AIHA), acquired hemophilia A (AHA), and immune thrombocytopenia (ITP). Rituximab induces profound B-cell depletion, reducing the titer of immunoglobulins and autoreactive antibodies, but secondary hypogammaglobulinemia increases risk of infections. We performed a retrospective, multicentric study across seven Italian centers to compare two cohorts of patients with either indolent NHL or ADHI treated with rituximab between March 2014 and March 2024. We evaluated the incidence and characteristics of infections and common antimicrobial prophylaxis adopted according to local clinical practice, in the absence of shared guidelines for ADHI. We included 285 patients (52% female; median age 55 years). The ADHI cohort comprised 187 patients (65%; 97 ITP, 78 AIHA, 12 AHA), while the control group included 98 i-NHL patients (34%). We documented 65 infectious events occurring in 65\/285 patients (22.8%). Infection-related mortality occurred in 9 patients (4%). When stratified, the cumulative 180-day incidence of infections was 9.4% (IC95% 8.8%-10%) for NHL patients and 13.7% for ADHI (IC95% 12.2%-14.2%). Multivariate analysis identified prophylaxis (OR 2.62,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.014) and post-treatment hypogammaglobulinemia (OR 2.73\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004) as risk factors. The risk of infection in patients with ADHI is high and comparable to that observed in NHL. Therefore, close monitoring of IgG levels is strongly advised, and mortality can be contained through rigorous antimicrobial stewardship.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07047-4","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:09:11Z","timestamp":1778296151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-0481","authenticated-orcid":false,"given":"Salvatore","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0870-6097","authenticated-orcid":false,"given":"Riccardo","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-2191","authenticated-orcid":false,"given":"Simona","family":"Raso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-5313","authenticated-orcid":false,"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariantonietta","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6913-8268","authenticated-orcid":false,"given":"Marta","family":"Mattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4772-3892","authenticated-orcid":false,"given":"Tania","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fanciullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-9635","authenticated-orcid":false,"given":"Giovanni Manfredi","family":"Assanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7727-2766","authenticated-orcid":false,"given":"Giacinto Luca","family":"Pedone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2898-5241","authenticated-orcid":false,"given":"Eugenio","family":"Santacroce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0868-5676","authenticated-orcid":false,"given":"Uros","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-3338","authenticated-orcid":false,"given":"Gaetano","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3993-2097","authenticated-orcid":false,"given":"Manuela Giuseppa","family":"Ingrasc\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1487-5812","authenticated-orcid":false,"given":"Mario","family":"Biglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-9964","authenticated-orcid":false,"given":"Claudia","family":"Cammarata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-3766","authenticated-orcid":false,"given":"Silvio","family":"Ligia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-8379","authenticated-orcid":false,"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-447X","authenticated-orcid":false,"given":"Cristina","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-6508","authenticated-orcid":false,"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-2936","authenticated-orcid":false,"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"4","key":"7047_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18773\/austprescr.2016.053","volume":"39","author":"KL Randall","year":"2016","unstructured":"Randall KL (2016) Rituximab in autoimmune diseases. Aust Prescr 39(4):131\u2013134. https:\/\/doi.org\/10.18773\/austprescr.2016.053","journal-title":"Aust Prescr"},{"issue":"10","key":"7047_CR2","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R et al (2017) Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther 34(10):2232\u20132273. https:\/\/doi.org\/10.1007\/s12325-017-0612-x","journal-title":"Adv Ther"},{"issue":"1","key":"7047_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/ijms27010046","volume":"27","author":"D Chatzis","year":"2026","unstructured":"Chatzis D, Banos A, Fanouriakis A, Karampitsakos T, Tzilas V (2026) Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications. Int J Mol Sci 27(1):46. https:\/\/doi.org\/10.3390\/ijms27010046","journal-title":"Int J Mol Sci"},{"issue":"10","key":"7047_CR4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1182\/blood.2019003808","volume":"137","author":"W Barcellini","year":"2021","unstructured":"Barcellini W, Fattizzo B (2021) How I treat warm autoimmune hemolytic anemia. Blood 137(10):1283\u20131294. https:\/\/doi.org\/10.1182\/blood.2019003808","journal-title":"Blood"},{"key":"7047_CR5","doi-asserted-by":"publisher","unstructured":"Cooper N, Ghanima W (2019) Immune Thrombocytopenia. Solomon CG (ed) N Engl J Med 381(10):945-955 https:\/\/doi.org\/10.1056\/NEJMcp1810479","DOI":"10.1056\/NEJMcp1810479"},{"issue":"7","key":"7047_CR6","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","volume":"105","author":"A Tiede","year":"2020","unstructured":"Tiede A, Collins P, Knoebl P et al (2020) International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 105(7):1791\u20131801. https:\/\/doi.org\/10.3324\/haematol.2019.230771","journal-title":"Haematologica"},{"issue":"12","key":"7047_CR7","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.3390\/jcm9124034","volume":"9","author":"I Murakhovskaya","year":"2020","unstructured":"Murakhovskaya I (2020) Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 9(12):4034. https:\/\/doi.org\/10.3390\/jcm9124034","journal-title":"J Clin Med"},{"issue":"15","key":"7047_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMra2033982","volume":"385","author":"S Berentsen","year":"2021","unstructured":"Berentsen S, Barcellini W (2021) Autoimmune Hemolytic Anemias. N Engl J Med 385(15):1407\u20131419. https:\/\/doi.org\/10.1056\/NEJMra2033982","journal-title":"N Engl J Med"},{"key":"7047_CR9","doi-asserted-by":"publisher","first-page":"9992086","DOI":"10.1155\/2021\/9992086","volume":"2021","author":"Y Dong","year":"2021","unstructured":"Dong Y, Yue M, Hu M (2021) The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. Biomed Res Int 2021:9992086. https:\/\/doi.org\/10.1155\/2021\/9992086","journal-title":"Biomed Res Int"},{"issue":"1","key":"7047_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ajh.27128","volume":"99","author":"P Wang","year":"2024","unstructured":"Wang P, Zhou R, Xue F et al (2024) Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial. Am J Hematol 99(1):28\u201337. https:\/\/doi.org\/10.1002\/ajh.27128","journal-title":"Am J Hematol"},{"issue":"6","key":"7047_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","volume":"130","author":"TS Athni","year":"2023","unstructured":"Athni TS, Barmettler S (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol 130(6):699\u2013712. https:\/\/doi.org\/10.1016\/j.anai.2023.01.018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"7047_CR12","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open 1(7):e184169. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4169","journal-title":"JAMA Netw Open"},{"issue":"5","key":"7047_CR13","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s00277-025-06296-z","volume":"104","author":"H Zhao","year":"2025","unstructured":"Zhao H, Su R, Luo J, Liu L (2025) Incidence and risk factors of severe infections in diffuse large B-cell lymphoma patients undergoing immunochemotherapy. Ann Hematol 104(5):2869\u20132879. https:\/\/doi.org\/10.1007\/s00277-025-06296-z","journal-title":"Ann Hematol"},{"issue":"4","key":"7047_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"issue":"4","key":"7047_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P et al (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15(4):424\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(14)70027-0","journal-title":"Lancet Oncol"},{"issue":"9","key":"7047_CR16","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1111\/j.1349-7006.2011.02001.x","volume":"102","author":"K Tobinai","year":"2011","unstructured":"Tobinai K, Igarashi T, Itoh K et al (2011) Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. Cancer Sci 102(9):1698\u20131705. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02001.x","journal-title":"Cancer Sci"},{"issue":"2","key":"7047_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3899\/jrheum.2023-0623","volume":"51","author":"YS Sun","year":"2024","unstructured":"Sun YS, Huang DF, Chen WS et al (2024) Risk Factors and Incidence of Serious Infections in Patients With Systemic Lupus Erythematosus Undergoing Rituximab Therapy. J Rheumatol 51(2):160\u2013167. https:\/\/doi.org\/10.3899\/jrheum.2023-0623","journal-title":"J Rheumatol"},{"key":"7047_CR18","doi-asserted-by":"publisher","first-page":"110342","DOI":"10.1016\/j.intimp.2023.110342","volume":"120","author":"X Boumaza","year":"2023","unstructured":"Boumaza X, Lafaurie M, Treiner E et al (2023) Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases. Int Immunopharmacol 120:110342. https:\/\/doi.org\/10.1016\/j.intimp.2023.110342","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"7047_CR19","doi-asserted-by":"publisher","first-page":"e0122171","DOI":"10.1371\/journal.pone.0122171","volume":"10","author":"X Jiang","year":"2015","unstructured":"Jiang X, Mei X, Feng D, Wang X (2015) Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PLoS ONE 10(4):e0122171. https:\/\/doi.org\/10.1371\/journal.pone.0122171","journal-title":"PLoS ONE"},{"issue":"11","key":"7047_CR20","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1002\/art.42541","volume":"75","author":"JW Park","year":"2023","unstructured":"Park JW, Curtis JR, Choi SR et al (2023) Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis Rheumatol 75(11):2036\u20132044. https:\/\/doi.org\/10.1002\/art.42541","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"7047_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM et al (2022) Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol 149(5):1525\u20131560. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.025","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"7047_CR22","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. CLIN INFECT DIS 46(12):1813\u20131821. https:\/\/doi.org\/10.1086\/588660","journal-title":"CLIN INFECT DIS"},{"key":"7047_CR23","unstructured":"Comprehensive Analysis for Clinicopathological Research \u2022 ClinicoPath. https:\/\/www.serdarbalci.com\/ClinicoPathJamoviModule\/. Accessed 21 Dec 2025"},{"issue":"9978","key":"7047_CR24","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","volume":"385","author":"W Ghanima","year":"2015","unstructured":"Ghanima W, Khelif A, Waage A et al (2015) Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 385(9978):1653\u20131661. https:\/\/doi.org\/10.1016\/S0140-6736(14)61495-1","journal-title":"Lancet"},{"issue":"22","key":"7047_CR25","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","volume":"124","author":"M Khellaf","year":"2014","unstructured":"Khellaf M, Charles-Nelson A, Fain O et al (2014) Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 124(22):3228\u20133236. https:\/\/doi.org\/10.1182\/blood-2014-06-582346","journal-title":"Blood"},{"issue":"3","key":"7047_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00277-021-04438-7","volume":"100","author":"S Raso","year":"2021","unstructured":"Raso S, Napolitano M, Arrigo G et al (2021) Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis. Ann Hematol 100(3):653\u2013659. https:\/\/doi.org\/10.1007\/s00277-021-04438-7","journal-title":"Ann Hematol"},{"issue":"5","key":"7047_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/cid\/ciaa127","volume":"72","author":"S Stabler","year":"2021","unstructured":"Stabler S, Giovannelli J, Launay D et al (2021) Serious Infectious Events and Immunoglobulin Replacement Therapy in Patients With Autoimmune Disease Receiving Rituximab: A Retrospective Cohort Study. Clin Infect Dis 72(5):727\u2013737. https:\/\/doi.org\/10.1093\/cid\/ciaa127","journal-title":"Clin Infect Dis"},{"issue":"1","key":"7047_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1182\/bloodadvances.2024013067","volume":"9","author":"Y Zadro","year":"2025","unstructured":"Zadro Y, Lafaurie M, Michel M, Lapeyre-Mestre M, Moulis G (2025) Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study. Blood Adv 9(1):231\u2013238. https:\/\/doi.org\/10.1182\/bloodadvances.2024013067","journal-title":"Blood Adv"},{"issue":"4","key":"7047_CR29","doi-asserted-by":"publisher","first-page":"e70082","DOI":"10.1002\/jha2.70082","volume":"6","author":"C Piatek","year":"2025","unstructured":"Piatek C, Murakhovskaya I, Karaouni A et al (2025) Real-World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study. EJHaem 6(4):e70082. https:\/\/doi.org\/10.1002\/jha2.70082","journal-title":"EJHaem"},{"issue":"19","key":"7047_CR30","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/bloodadvances.2021004626","volume":"5","author":"ME Mingot-Castellano","year":"2021","unstructured":"Mingot-Castellano ME, Pardos-Gea J, Haya S et al (2021) Management of acquired hemophilia A: results from the Spanish registry. Blood Adv 5(19):3821\u20133829. https:\/\/doi.org\/10.1182\/bloodadvances.2021004626","journal-title":"Blood Adv"},{"issue":"5","key":"7047_CR31","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/hae.15037","volume":"30","author":"V Nummi","year":"2024","unstructured":"Nummi V, Hiltunen L, Szanto T, Poikonen E, Lehtinen AE (2024) Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes. Haemophilia 30(5):1130\u20131137. https:\/\/doi.org\/10.1111\/hae.15037","journal-title":"Haemophilia"},{"issue":"5","key":"7047_CR32","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","volume":"161","author":"JW Park","year":"2022","unstructured":"Park JW, Curtis JR, Jun KI et al (2022) Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab. Chest 161(5):1201\u20131210. https:\/\/doi.org\/10.1016\/j.chest.2021.11.007","journal-title":"Chest"},{"issue":"7","key":"7047_CR33","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.cmi.2018.02.031","volume":"24","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Cordonnier C (2018) Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? Clin Microbiol Infect 24(7):678\u2013679. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.031","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"7047_CR34","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.leukres.2015.10.013","volume":"39","author":"F De Angelis","year":"2015","unstructured":"De Angelis F, Tosti ME, Capria S et al (2015) Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. Leuk Res 39(12):1382\u20131388. https:\/\/doi.org\/10.1016\/j.leukres.2015.10.013","journal-title":"Leuk Res"},{"issue":"6","key":"7047_CR35","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","volume":"19","author":"M Mikulska","year":"2019","unstructured":"Mikulska M, Cesaro S, de Lavallade H et al (2019) Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19(6):e188-e199. https:\/\/doi.org\/10.1016\/S1473-3099(18)30601-7","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"7047_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA et al (2023) 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken) 75(3):449\u2013464. https:\/\/doi.org\/10.1002\/acr.25045","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"7047_CR37","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1080\/10428194.2025.2540442","volume":"66","author":"A Xiao","year":"2025","unstructured":"Xiao A, Chen L, Pak S et al (2025) Real-world infectious complications of CD3\/CD20 bispecific antibodies in relapsed\/refractory non-Hodgkin lymphoma. Leuk Lymphoma 66(12):2260\u20132268. https:\/\/doi.org\/10.1080\/10428194.2025.2540442","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"7047_CR38","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3390\/cancers17152426","volume":"17","author":"A Szymczyk","year":"2025","unstructured":"Szymczyk A, Drozd-Soko\u0142owska J, Hus I (2025) Infectious Complications in Patients with B-Cell Non-Hodgkin Lymphoma Treated with Bispecific Antibodies. Cancers 17(15):2426. https:\/\/doi.org\/10.3390\/cancers17152426","journal-title":"Cancers"},{"key":"7047_CR39","doi-asserted-by":"publisher","unstructured":"Huang H, Wei X Therapeutic potential of CD20\/CD3 bispecific antibodies in the treatment of autoimmune diseases. Rheumatol Immunol Res 5(4):209\u2013216. https:\/\/doi.org\/10.1515\/rir-2024-0029","DOI":"10.1515\/rir-2024-0029"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07047-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07047-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07047-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:01:44Z","timestamp":1783976504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07047-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7047"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07047-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GMA Advisory board Takeda, Jazz, Research Funding Gilead, Travel Grant Lilly, Beigene. M.N. acted as consultant for Bayer, CSL Behring, Novonordisk and received speaker fees from Bayer, Sanofi, Takeda, Sobi, Novonordisk, CSL Behring, Amgen, Novartis, Grifols, Kedrion. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}